CLINICAL APPLICATIONS (CA)

(F1211) MESENCHYMAL STEM CELLS REGULATES THE IMMUNE RESPONSE IN DIABETES TYPE 2: A FUNCTIONAL ANALYSIS.

(F1212) COMPARATIVE STUDY OF SERUM-FREE CULTURE MEDIA ON THE GROWTH AND FUNCTION OF UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS

(F1213) Optimising stem cell derived therapies for degenerative disease: Assessing clinical grade human embryonic stem cell lines for age-related macular degeneration associated risk alleles.

(F1214) INVESTIGATING GENOME EDITING AS A POTENTIAL THERAPEUTIC FOR LATE-ONSET RETINAL DEGENERATION

(F1215) HIGH-DENSITY EXPANSION AND METABOLIC CHARACTERIZATION OF HUMAN ADIPOSE AND WHARTON'S JELLY MESENCHYMAL STEM CELLS IN SCALABLE MICROCARRIER SUSPENSION CULTURE

(F1216) GENERATION OF A CARDIAC-SPECIFIC RECOMBINANT PROTEIN TOOLBOX FOR DIRECT CARDIAC REPROGRAMMING AND OTHER BIOMEDICAL APPLICATIONS

(F1217) DEVELOPMENT OF AN AUTOMATED 3D PLATFORM FOR MANUFACTURING PLURIPOTENT STEM CELL-BASED CLINICAL CELL THERAPY PRODUCTS

(F1218) HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED OVARIAN IMPLANTS TO PREVENT THE ADVERSE EFFECTS OF MENOPAUSE

(F1219) Advanced hPSC bioprocessing via 3D inoculation from cryopreserved cell stocks

(F1220) ADVANCING ALLOGENEIC CAR-T CELL THERAPY: OVERCOMING CHALLENGES IN AUTOLOGOUS GRAFTING AND LENTIVIRAL TRANSDUCTION THROUGH IPSC AND CRISPR TECHNOLOGIES FOR T-CELL MALIGNANCIES

(F1221) Off-the-Shelf Dopaminergic Progenitors Derived from iPSCs for Improving Safety and Functional Restoration in Parkinsonian Rats

(F1222) FEASIBILITY OF USING STEM-CELL DERIVED HUMAN TROPHOBLASTS FOR MASS PROPAGATION OF LIVE ATTENUATED VACCINE STRAINS OF SARS-CoV-2 AND OTHER VIRUSES

(F1223) DECREASED A-TO-I RNA EDITING AND HYPEREXCITABILITY ASSOCIATED WITH ENHANCED CHOLESTEROL BIOSYNTHESIS IN LOWER MOTOR NEURONS OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS

(F1224) POST-MARKET STUDY OF THE CLINICAL EFFICACY OF HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED OVARIAN SUPPORT CELLS FOR INFERTILITY TREATMENT

(F1225) TRASIENT RORβ KNOCKDOWN BY CELL-PENETRATING siRNA ALLEVIATES RETINAL DEGENERATION CAUSED BY PROTEOTOXICITY

(F1226) PSEUDO-COST-EFFECTIVENESS ANALYSIS OF AUTOLOGOUS ADIPOSE-DERIVED MESENCHYMAL STEM CELL THERAPY FOR K/L 3&4 PATIENTS WITH KNEE OSTEOARTHRITIS COMPARED TO TOTAL KNEE ARTHROPLASTY

(F1227) IN VIVO SINGLE AND DUAL TRANSDUCTION OF AAV6 IN EXPANDED NON-MOBILIZED HAEMATOPOIETIC STEM CELLS FROM TRANSFUSION-DEPENDENT THALASSEMICS IN HUMANIZED MICE

(F1228) DIRECTED DIFFERENTIATION OF MRNA-REPROGRAMMED IPSCS VIA BIOREACTORS GENERATES CLINICALLY RELEVANT YIELDS OF NEURAL STEM AND PROGENITOR CELLS THAT CAN BE ENGINEERED TO SECRETE THERAPEUTIC PROTEINS

(F1229) Potency Assay Matrix for Dopaminergic Neuron Precursor Cell Replacement Therapy for Parkinson’s Disease

(F1230) HOLOCORE: A PAN-EUROPEAN PHASE 4 CLINICAL TRIAL ON THE EFFICACY AND SAFETY OF HOLOCLAR FOR LIMBAL STEM CELL DEFICIENCY

(F1231) Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells: A Scalable and Versatile Source of Extracellular Vesicles for Regenerative Medicine

(F1232) ENHANCED SKIN CELL REJUVENATION BY INITIATION PHASE PARTIAL REPROGRAMMING USING AI-DESIGNED CIRCRNA-EXPRESSED PHASE SEPARATION-DEFICIENT TRANSCRIPTIONAL FACTORS

(F1233) A SCALABLE CULTURE SYSTEM FOR DIFFERENTIATION OF IMMUNE CELLS FROM PLURIPOTENT STEM CELLS

(F1234) INSIGHTS INTO THE CLINICAL DEVELOPMENT OF REGENERATIVE MEDICAL PRODUCTS BY REGULATORY FRAMEWORK

(F1235) Monitoring Success: The Long-term Safety and Efficacy of Hematopoietic Stem Cell Gene Therapy

(F1236) OPTIMIZED CONDITIONS FOR STEM CELL-DERIVED EXTRACELLULAR VESICLES IN BIOREACTOR CULTIVATION

(F1237) SCALING MANUFACTURING AND LOT RELEASE FOR OFF-THE-SHELF ALLOGENEIC HIPSC-DERIVED THERAPY FOR INFERTILITY

(F1238) STEM CELL THERAPY FOR CHRONIC LUMBAR DISC DISEASE: PHASE 2 CLINICAL SAFETY AND FEASIBILITY DATA OF INTRADISCAL INJECTIONS OF HYPOXIC CULTURED MESENCHYMAL STEM CELLS

(F1239) AUTOMATION IN CELL THERAPY PRODUCTION: ENHANCING SAFETY, REPRODUCIBILITY, AND COST-EFFECTIVENESS OF HESC-DERIVED RPE CELLS

(F1240) GENERATION OF STEM CELL DERIVED ISLETS WITH ENHANCED PURITY AND FUNCTIONALITY FOR TREATMENT OF TYPE-1 DIABETES

(F1241) Holoclar lessons: biological and clinical insights learnt from Autologous Cultivated Limbal Stem Cells Transplantation for regenerating corneal epithelium in limbal stem cell deficiency patients.

(F1242) SCALABLE HEMATOPOIETIC STEM CELL EXPANSION IN STIRRED-TANK BIOREACTORS FOR ADVANCING CELL IMMUNOTHERAPIES

(F1243) CELL TRANSPLANT DELIVERY OF MAMBALGIN-1, AN ACID-SENSING ION CHANNEL INHIBITOR SNAKE PEPTIDE, COULD NUMB PAIN PERCEPTION

(F1244) INTER- AND INTRA-DONOR VARIABILITY OF IPSC GENERATED FOM HUMAN SKIN PUNCH BIOPSIES VIA AN ACCELERATED AND VALIDATED PIPELINE USING NON-INTEGRATIVE RNA-BASED REPROGRAMMING

(F1245) LARGE SCALE AND SERUM-FREE DIFFERENTIATION AND CULTIVATION OF HUMAN PSCS INTO ENDOTHELIAL CELLS USING A CLOSED SEMIAUTOMATED CULTIVATION PLATFORM

(F1246) VERSATILE HIGH-SPEED MICROFLUIDIC CELL SORTING OF HUMAN PLURIPOTENT STEM CELLS AND THEIR DERIVATIVES

(F1247) FINDING HOPE IN UNCERTAINTY. PATIENTS' PERSPECTIVES ON CONSIDERING STEM CELL THERAPY FOR INBORN ERRORS OF IMMUNITY.

(F1248) SAFETY AND EXPLORATORY EFFICACY OF HUMAN ALLOGENEIC WHARTONS' JELLY-DERIVED MESENCHYMAL STEM CELLS IN PATIENTS WITH CMT1A: THE PHASE 1 TRIAL

(F1249) HYPOIMMUNE IPSC-DERIVED MACROPHAGES ENGINEERED TO EXPRESS IL-12 ACTIVATE LYMPHOCYTES AGAINST PLATINUM-RESISTANT OVARIAN CANCER

(F1250) SCALABLE MSC EXPANSION WITH CELLFIBER® TECHNOLOGY AS A COST-EFFECTIVE MANUFACTURING PLATFORM

(F1251) TOWARDS ENHANCING CELL REPLACEMENT THERAPIES FOR PARKINSON’S DISEASE – A NOVEL APPROACH FOR ASSESSING CLONAL EXPANSION AND GRAFT DIVERSIFICATION

(F1252) BIODISTRIBUTION ASSESSMENT OF HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CELL THERAPY PRODUCT

(F1253) USING HUMAN PLURIPOTENT STEM CELLS DERIVED CARDIOVASCULAR CELLS FOR DISEASE MODELING AND TISSUE REPAIR

(F1254) AN INTEGRATED APTAMER-BASED PLATFORM FOR EFFICIENT EXOSOME ISOLATION, MOLECULAR ANALYSIS, AND REAL-TIME DETECTION

(F1255) GelMA and polydopamine nanoparticles promote the efficacy of MSC spheroids on diabetic wound through an integrated living dressing

(F1256) iPSC-based therapy for Parkinson’s disease

(F1257) ENHANCING THE ANTI-INFLAMMATORY PROPERTIES OF MSCS AND MSC-EVs BY OVEREXPRESSING IL-10

(F1258) CHARACTERISTICS OF MESENCHYMAL STEM CELL THERAPEUTICS CULTURED IN 3D USING GELATIN HYDROGEL SCAFFOLDS AND THEIR EFFICACY IN REFRACTORY INTESTINAL INFLAMMATION

(F1259) LONG-TERM SAFETY OF NOVEL DUAL INJECTION OF HUMAN NEURAL STEM CELLS (hNSCs) & PEPTIDE CHEMOATTRACTANT IN THE ALS SOD1 MOUSE MODEL

(F1260) "IT'S REALLY AN ADVENTURE": A QUALITATIVE STUDY EXPLORING EXPERIENCES OF PROFESSIONALS INVOLVED IN WORKING WITH ADVANCED THERAPEUTICS IN THE NETHERLANDS

(F1261) Creation of the first global continuing education course for healthcare professionals on stem cell medicine

(F1262) MODULATION OF SERCA2A OF INTRA-MYOCYTIC CALCIUM TRAFFICKING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (MUSIC-HFREF) AND STEM CELL MODELS OF HEART FAILURE

(F1263) NOVEL MEMBRANE STIRRER FOR EFFICIENT AERATION AT HIGH CELL DENSITY BIOPROCESSING OF HUMAN PLURIPOTENT STEM CELLS

(F1264) ENHANCED GENETIC STABILITY OF HUMAN PLURIPOTENT STEM CELL CULTURES WHEN SINGLE-CELL PASSAGING USING ETESR™

(F1265) A BASE EDITING PLATFORM OPTIMIZED FOR HEMATOPOIETIC STEM AND PROGENITOR CELLS RETAINS STEMNESS AND DIFFERENTIATION POTENTIAL

(F1266) A SINGLE-STEP PROCESS FOR NON-VIRAL ENGINEERING HYPOIMMUNOGENIC PLURIPOTENT STEM CELLS WITH THE PIN-POINTTM BASE EDITING PLATFORM

(F1267) TOWARDS THE SCALABLE PRODUCTION OF IPSC-DERIVED NK CELLS

(F1268) FABRICATION OF ECM-MIMICKING HYDROGEL FOR ADIPOSE TISSUE ENGINEERING

(F1269) Transplantation of encapsulated liver organoids for the treatment of liver failure

(F1270) CELL THERAPY SCALE-UP: BIOPROCESS DEVELOPMENT FOR THE PRODUCTION OF HEMATOPOIETIC CELLS

(F1271) ABSTRACT PREVIEW: LIPID NANOPARTICLES MEDIATED DUAL GENE KNOCK-OUT (KO) IN INDUCE PLURIPOTENT STEM CELLS (IPSCS)

(F1272) OPTIMIZING PLURIPOTENT STEM CELL SPHEROID GROWTH IN LITER SCALE BIOREACTORS THROUGH THE USE OF CONSTANT MEDIUM PERFUSION

(F1273) GENERATION OF HUMAN iPSC-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND DIFFERENTIATION TO FUNCTIONAL iNK CELLS IN A FLEXIBLE AND FEEDER-FREE CULTURE SYSTEM

(F1274) APPLICATION OF INDUCED PLURIPOTENT STEM CELL-DERIVED MITOCHONDRIA TRANSFER FOR IN VITRO OSTEOGENESIS

(F1275) Novel Coated Contact Lenses as Therapeutic Scaffolds for Stem Cell Culture and Transplantation

(F1276) INJECTABLE MICROGEL PLATFORM FOR CELL-BASED REGENERATION IN INTERVERTEBRAL DISC DEGENERATION

(F1277) CLINICAL SCALE NON-VIRAL GENE EDITING AND FEEDER-FREE PRODUCTION OF CAR-NK CELLS

(F1278) STRUCTURAL CHARACTERIZATION OF THE 20Q11.21 REARRANGEMENT RECURRENTLY OBSERVED IN HUMAN PLURIPOTENT STEM CELLS

(F1279) STABLE EXPRESSION SYSTEM DURING DIFFERENTIATION OF HUMAN IPSCS INTO MSCS

(F1280) WHAT REALLY ARE THE TROPHIC REQUIREMENTS OF MATURING HUMAN PLURIPOTENT STEM CELL-DERIVED NEURONS?

(F1281) Comparison of the iPSCs and iPSC-Derived Retinal Pigment Epithelial Cells in Treating Sodium Iodate-Induced Dry-Type Age-Related Macular Degeneration

(F1282) NOVEL POROUS MICROSCAFFOLD ENABLES MACROPHAGE DIFFERENTIATION AND PROLIFERATION FROM HPSCS FOR THERAPEUTIC APPLICATIONS

(F1283) SCALING UP THE EXPANSION OF MESENCHYMAL STEM CELLS DERIVED FROM WHARTON'S JELLY USING MICROCARRIERS IN BIOREACTORS FOR CLINICAL APPLICATIONS

(F1284) CHARACTERISTICS OF ENDOMETRIAL STEM CELLS AND EXTRACELLULAR VESICLES ACCORDING TO THE ESTRUS CYCLE

(F1285) INNOVATIVE POLYCLONAL GENE EDITING TECHNIQUES FOR GENERATING FAILSAFE AND IMMUNE EVADING iPSCs: ADVANCING ENGINEERED CELL THERAPIES

(F1286) STREAMLINING CELLULAR REPROGRAMMING: A CLINICAL-GRADE WORKFLOW FOR MANUFACTURING ALLOGENEIC AND AUTOLOGOUS iPSCs

(F1287) Cell based mRNA delivery promotes cartilage improvement in osteoarthritic rat model

(F1288) IMMUNOLOGICAL DRIFTING: IMMUNOMODULATORY EFFECT OF PLACENTA-DERIVED MESENCHYMAL STEM CELLS ON PERIPHERAL BLOOD MONONUCLEAR CELLS INFECTED WITH SARS-COV-2

(F1289) Development of targeted delivery of regenerative therapies derived from non-modified and modified stem cells

(F1290) VERIFICATION OF TISSUE REGENERATION EFFECTS IN A HIND LIMB ISCHEMIA AND SKIN ULCER MODEL MOUSE USING NOVEL CELL THERAPY WITH EX VIVO CULTURED PERIPHERAL BLOOD MONONUCLEAR CELLS

(F1291) EARLY AND PROGRESSIVE DYSFUNCTION OF ENDOGENOUS BONE MARROW MESENCHYMAL STROMAL CELLS IN PARKINSON’S DISEASE: IMPLICATIONS FOR REGENERATIVE THERAPY

(F1292) ENHANCING T CELL IMMUNOTHERAPY FOR SOLID TUMORS USING A NOVEL FUNCTIONAL SORTING APPROACH WITH A MICROFLUIDIC DEVICE.

(F1293) HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELL THERAPY FOR SEVERE BRONCHOPULMONARY DYSPLASIA REFRACTORY TO CONVENTIONAL THERAPY: A PHASE I CLINICAL TRIAL

(F1294) ENHANCING TISSUE REGENERATION USING PLACENTAL STEM CELL-DERIVED EXTRACELLULAR VESICLES INTEGRATED WITH THERMOGEL

(F1295) MSC-DERIVED EXTRACELLULAR VESICLES OBTAINED USING PS-AFFINITY METHOD SHOWED HIGHER ANTI-INFLAMMATORTY ACTIVITIES THAN OTHER CONVENTIONAL METHODS.

(F1296) HETEROGENEITY OF MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES: INFLUENCE OF CELL ORIGIN AND CULTURE CONDITIONS ON MOLECULAR CARGO AND SKIN REGENERATIVE POTENTIAL

(F1297) The Role of Aging in Modulating Adipose-Derived Mesenchymal Stem Cell Extracellular Vesicles: Insights into Immunomodulation and Tissue Repair

(F1298) THERAPEUTIC POTENTIAL OF EX VIVO CULTURED MONONUCLEAR CELLS FOR HAIR REGENERATION: PRECLINICAL AND CLINICAL EVALUATION IN ALOPECIA TREATMENT

(F1299) MicroRNA profile including A-to-I editome as diagnostic and pharmacodynamics markers for ALS

(F1300) ENHANCEMENT OF ERYTHROCYTE DIFFERENTIATION VIA THE PRECISE INTRODUCTION OF A NATURALLY OCCURRING VARIANT IN EPOR USING CRISPR/CAS9 GENOME EDITING

(F1301) Paracrine Effects of MNCQQ Cell-Derived Conditioned Medium Promote Angiogenesis and Wound Healing.

(F1302) ADVANCING AMNIOTIC STEM CELL THERAPEUTICS THROUGH OPTIMIZED 3D CULTURE SYSTEMS

(F1303) Validating GMP-conform Cryopreservation of Human Umbilical Cord Tissue for downstream Isolation of Wharton’s Jelly MSCs

(F1304) INDUCED RETINAL PROGENITOR CELLS FOR TREATING PHOTORECEPTOR DEGENERATION DISEASES

(F1305) PRECLINICAL EVALUATION OF AUTOLOGOUS IPSC-DERIVED MIDBRAIN DOPAMINERGIC PROGENITORS FOR THE TREATMENT OF PARKINSON’S DISEASE, UX-DA001

(F1306) GENETICALLY ENHANCED MESENCHYMAL STEM CELLS SIGNIFICANTLY IMPROVED SURVIVAL OF SEPSIS IN ANIMALS AND APPEARED WELL TOLERATED IN A PHASE 1 SAFETY TRIAL OF SEPTIC SHOCK PATIENTS

(F1307) iPSC-Derived Endothelial Cells Promote Neovascularization and Limb Salvage in Peripheral Artery Disease

(F1308) EXPLORING THE THERAPEUTIC POTENTIAL OF NETRIN-1 PRIMED MSC-DERIVED SECRETOME IN WOUND HEALING

(F1309) Facet-based DNA nanostructures for enhanced stability of nucleic acids in vivo

(F1311) Aptamer-Embedded DNA Supramolecular Hydrogels Enhance Cell Protection, Retention, and Chondrogenic Differentiation to Promote Cartilage Repair

(F1312) DEVELOPMENT OF XENO-FREE, FAST-DISSOLVING MICROCARRIERS FOR SCALABLE STEM CELL THERAPY APPLICATIONS

(F1313) XT-THRIVE, A NON-DMSO ALTERNATIVE TO CRYOSTOR FOR SUPERIOR CRYOPRESERVATION OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS

(F1314) Progenitor reprogramming for cellular rejuvenation by defined factors

(F1315) DERIVATION OF ENTERIC NEURAL PROGENITORS FROM HUMAN INDUCED PLURIPOTENT STEM CELL AND EVALUATION OF THERAPEUTIC POTENTIAL AS A SOURCE FOR CELL-BASED THERAPY OF HIRSCHSPRUNG’S DISEASE

(F1316) SCALABLE STEM CELL-DERIVED NATURAL KILLER CELL DIFFERENTIATION IN AN IN VITRO FEEDER-FREE SYSTEM

(F1317) A SIMPLE AND FLEXIBLE CELL FACTOR ASSAY PANEL FOR CLINICAL STUDY SAMPLE ANALYSIS

(F1318) A TRANSCRIPTIONAL ATLAS OF THE PUBERTAL HUMAN GROWTH PLATE CLARIFIES THE MOLECULAR MECHANISM FOR GROWTH HORMONE-INDUCED GROWTH

(F1319) EVALUTATING CLOAKED-FAIL/SAFE CELLS AS A UNIVERSAL ALLOGENIC SOURCE FOR TRANSPLANTATION IN HUMANIZED MOUSE MODELS

(F1320) REVERSIBLE IMMORTALIZATION FACILITATES THE LARGE-SCALE PRODUCTION OF IL10-ENRICHED EXOSOMES FOR OSTEOARTHRITIS THERAPY

(F1321) Improved Vascularization of 3D Biofabricated Human Stem Cell-Derived Kidney Tissue

(F1322) AUTOMATED IPSC CULTURE AND DIFFERENTIATION USING THE MYTOS IDEM PLATFORM: ADVANCING SCALABLE REGENERATIVE MEDICINE

(F1323) The Therapeutic Effects of Adipose Stem Cell Extracellular Vesicles on Lymphedema

(F1324) REGIONAL SPECIFIC HUMAN SPINAL INTERNEURON FOR RESTORING SPECIFIC FUNCTION IN SPINAL CORD INJURY

(F1325) DEVELOPING A FLEXIBLE CELL PROFILING PLATFORM TO QUALIFY RAW CELLULAR MATERIALS AND FINAL THERAPEUTICS

(F1326) EXPLORING THE POTENTIAL OF EPSC-DERIVED NK CELLS IN A HUMAN 3D EMBRYOID BODY MODEL FOR IMMUNOTHERAPY APPLICATIONS

(F1327) TRANSPLANTATION OF HYALINE-CARTILAGE-LIKE TISSUES INDUCED FROM HUMAN PLURIPOTENT STEM CELL-DERIVED LIMB BUD-MESENCHYMAL CELLS TO A MINI PIG MODEL WITH OSTEOCHONDORAL DEFECTS

(F1328) SKIN PRECURSOR CELL DIFFERENTIATION FROM INDUCED PLUROPOTENT STEM CELLS AND APPLICATION OF SKIN PRECURSOR CELL-CONDITIONED MEDIUM IN SKIN BURNS: A PROMISING CANDIDATE FOR SKIN REGENERATION

(F1329) Aptamer-mediated targeting of MMP14 as a potential therapeutic for low bone mass

(F1330) GENOME-ENGINEERED PORCINE EXPANDED POTENTIAL STEM CELLS AS A NOVEL CELLULAR SOURCE FOR XENOTRANSPLANTATION

(F1331) CIRCULAR RNA-MEDIATED PARTIAL REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY FOR IDIOPATHIC PULMONARY FIBROSIS VIA REVERSING PATHOLOGICAL CELL STATES OF ALVEOLAR EPITHELIAL CELLS AND LUNG FIBROBLASTS

(F1332) CHIMERIC ANTIGEN RECEPTOR T CELLS FOR SELECTIVE TARGETING OF CANCER-EXPRESSING PODOCALYXIN

(F1333) Composite functional cardiac tissue sheets with hiPSC-CMs and hADSCs for treating myocardial infarction

(F1334) IL-24-IMSC: A NOVEL THERAPEUTIC STRATEGY TO REVERSE THE IMMUNOSUPPRESSIVE TUMOUR MICROENVIRONMENT IN NON-SMALL CELL LUNG CANCER

(F1335) Attempts to Direct Conversion of T Cells and ESCs/iPSCs into Retinal Progenitor-Like Cells by Small Molecule cocktails

(F1337) ENHANCING THE SUSTAINED RELEASE OF GROWTH FACTORS IN PRP PROCEDURES USING A FIBRIN FIBER

(F1338) IMPROVEMENT OF VISUAL FUNCTION AFTER RPE PROGENITOR CELL TRANSPLANTATION IN AMD PATIENTS

(F1339) THE ROLE OF FULL-LENGTH LAMININS IN ENHANCING IN VITRO CELLULAR MICROENVIRONMENTS